CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 148 enrolled
Drug / intervention
.9 normal saline placebo +1 moredrug
Likely dose
Group L (lidocaine) 1.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01619852
NCT01619852N/ACompleted
CompareCT.gov

The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain

Northwestern University·interventional·Posted Jun 14, 2012·Updated Nov 27, 2019

In Brief

A clinical study evaluating .9 normal saline placebo and Group L (lidocaine) for Surgery. Completed, enrolled 148 participants across 1 site.

Detailed Summary

The study seeks to investigate a safe and inexpensive strategy to reduce persistent post-surgical pain that can affect up to 60% of patients undergoing surgical procedures. Hypotheses: Perioperative systemic lidocaine reduces the persistence of chronic pain in patients undergoing surgical procedures.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSurgery
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2012
Enrollment StartJun 1, 2012
Primary CompletionJul 1, 2014
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.0 years ago

Interventions

.9 normal saline placebodrug

Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.

Group L (lidocaine)drug

Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.